Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

You may also like

27 May 2020

Clinical Genomics announces publication of Additional positive data reinforcing key benefits of COLVERA®

26 October 2010

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

17 March 2020

Vaxxas Publication in PLoS Medicine Reveals Groundbreaking Clinical Research on Broad Potential of Novel High-Density Microarray Patch (HD-MAP)

02 June 2021

Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine

22 July 2020

OneVentures Venture Credit Fund poised to invest $120M into Australian scaleups

05 August 2018

Australian First:-Israeli venture partnership launches new Venture Credit Fund to invest in high-growth technology companies

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor